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ABSTRACT 
The production of monoclonal antibodies and Fc fusion proteins form the largest 
and most rapidly expanding category of the biopharmaceuticals today with the annual 
sales exceeding USD$8 billion with the application across a wide range of diseases 
especially for the immunotherapy purpose.  With the growth of this class of 
biomolecules, significant thought on the most efficient downstream processing steps for 
monoclonal antibodies has been taken into the highly consideration by the manufacturer 
in order to obtain the highest yield with the highest purity of the product which is why 
the simulation study are crucial in this development. The objectives of this study are to 
propose the most suitable framework of downstream processing for monoclonal 
antibodies production in order to achieve highest purities of mAbs and to stimulate the 
propose framework using SuperPro Designer
®
 simulator.  The process was initially done 
via the disk stack centrifuge and followed by microfiltration in order to harvest the 
protein.  Three column of chromatography (Protein A affinity, anion exchange and 
hydrophobic interaction) were used to obtain the highest purity of the therapeutic.  Viral 
inactivation also was employed to free the product from the endotoxins and pyrogens.  
The propose steps then, was introduced into the SuperPro Designer
®
 simulator and the 
result obtained were 100% purity of IgG with 9.49345 g/L of concentration and 0.16687 
kg/batch with 76.3% of recovery of the product.   
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ABSTRAK 
 Penghasilan antibodi monoklonal dan protein fc-penyatuan telah membentuk 
satu bidang biofarmasi yang paling maju and pantas berkembang dengan jualan tahunan 
melebihi USD$8 Bilion mencakupi aplikasi dalam merawat pelbagai penyakit 
terutamanya dalam bidang terapi imun.  Dengan pertumbuhan kelas biokimia tersebut, 
proses hiliran untuk antibodi monoklonal telah dipandang  dengan serius oleh pengilang 
bagi mendapatkan hasil dan ketulenan tertinggi dan disinilah simulasi telah dianggap 
sesuatu yang perlu dalam mencapai pembangunan tersebut. Tujuan kajian ini dilakukan 
adalah untuk mencadangkan satu langkah kerja proses hiliran untuk antibodi 
monoklonal bagi mendapatkan hasil ketulenan yang tinggi dan seterusnyer 
mensimulasikan langkah kerja tersebut menggunakan simulasi SuperPro Designer
®
.  
Proses tersebut dimulai dengan proses penuaian sel menggunakan ceper pengemparan 
dan disusuli pula dengan penapis mikro.  Tiga kromatografi kolum (afiniti protein A, 
penukar anion, dan interaksi hidrofobia) digunakan untuk mencapai ketulenan tertinggi 
oleh terapeutik tersebut.  Penyahaktifan virus juga dipakai untuk mendapatkan hasil 
yang bebas daripada endotoksin dan phirogen.  Proses yang dicadangkan kemudian 
dimasukkan ke dalam simulasi SuperPro Designer
®
 dan hasil yang diperolehi seperti 
ketulenan Immunoglobulin G mencapai peratusan 100% dengan kepekatan 9.49345 g/L 
dan penghasilan 0.16687 kg/kumpulan dengan peratusan 76.3%. 
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 CHAPTER 1 
INTRODUCTION 
1.1 Background of Study 
 For the past ten years, biotechnology have been announced as one of five core 
technologies that will accelerate Malaysia`s transformation into a highly industrialized 
nation by 2020.  Government of Malaysia, trough the established of National 
Biotechnology Division under Ministry of Science, Technology and Innovative 
(MOSTI), carries the mission to spearhead the biotechnology development for wealth 
creation and social well-being by establishing Malaysia as the biotechnology centre 
through. 
 In next ten years, antibody-based therapies will be a major source of new 
therapies however, it is major bottleneck for the biotechnology industry, in the 
processing the biopharmaceuticals antibodies to meet clinical demand (Alberto et al., 
2003).  Monoclonal antibodies (mAbs) are the most widely used form of cancer 
immunotherapy. Monoclonal antibodies therapy uses antibodies outside the body which 
made in the lab, produce in large numbers rather than by a person‟s own immune.  This 
type of treatment is considered as one of a form of passive immunotherapy.  In 
biopharmaceutical industry, monoclonal antibodies have emerged as one of the most 
exciting therapeutic modalities (Abhinav et al., 2007).  In U.S and the European Union, 
there are nineteen monoclonal antibodies therapeutics has been approved by US food 
and Drug Administration (USFDA) for sale (Walsh, 2004) to treat cancer and transplant 
rejection and also use to combat autoimmune disease (Reichert, 2001). 
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A key segment of the production and marketing of any pharmaceutical product, 
whether it is an antibiotic, a peptide, or a complex protein, is the processing of the 
materials from its initial milieu (tissue, fermentation broth, etc.) to a pure form suitable 
for its intended use.  This key segment, termed downstream processing can be, and often 
is, a complicated series of isolation and purification steps which usually quite costly 
(Spears, 1993).  The recovery and purification steps of mAbs or downstream processing 
is aim to obtain a highly pure antibodies and to meet the USFDA specification which 
initially from mammalian cell culture supernatant.  This process implies the use of a 
combination of a various bioseparation techniques by exploiting the physical and 
chemical properties of the antibodies.  The purification of mAbs generally takes place in 
three phases which are a capture steps by which the mAbs present in hybridoma culture 
supernatant is separated from other sample components, an intermediate step by which 
the mAbs is isolated from contaminations similar in size or biochemical properties, and 
a cleaning step for the complete removal trace contaminant (Alberto et al., 2003). 
Product recovery methods which are effective, efficient, and well designed are 
essential in developing a downstream process which can deliver a marketable product to 
the public, and a financial return to the company.  Due to this circumstances, a new 
developed technology called a simulation process are required.  Process simulation have 
been realized, gives advantages to the development, evaluation and scale up of 
bioprocesses.  The opportunity to shorten time required for the development by allowing 
comparison of process alternatives so that various ideas can be synthesized and analyzed 
interactively in a short time (Rouf et al., 2001).  In this study, the commercial bioprocess 
simulator which is SuperPro Designer
® 
(SPD) version 6.0 (Intelligen, 1999), was 
assessed for evaluation of production of a biopharmaceutical from a recombinant 
mammalian cell culture. 
 The study aim to stimulate a new set of workflow created using the bioseparation 
principles, in the simulator to get an exact data sheets.  The study is the downstream 
processing of monoclonal antibodies production workflow, transforming into a 
framework of a simulator in the SuperPro Designer
® 
(SPD) main frame thus stimulate to 
give an overall mass balance and so do for each stream. 
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1.2 Problem Statement 
 Biotechnology manufacturing concerns must be able to design and implement 
purification schemes that are repeatable, reliable and meet current good manufacturing 
practice (GMP) guidelines.  The new generations of product from the biotechnology 
industries are more complex and are often quite labile.  Thus, in manufacturing of 
monoclonal antibodies, similar processes are use by majority; A batch/fed batch culture 
using mammalian cell followed by purification steps, that rely primarily on 
chromatography method with intermediate filtration and viral clearance operation (Farid, 
2007).  Downstream processing must be improved as the increasing titrates in 
mammalian cell culture by different kind of variety and innovative steps in purification.  
The critical part of the production process and can be significant proportion of the total 
manufacturing costs is the efficiency of recovery and purification (Abhinav et al., 2007). 
The nature of bioseparation for every biological product face several difficulty in 
order to do the downstream processing such as present in very low concentrations in the 
starting material from which they are purified.  In this study, mAbs are typically present 
in concentrations around 0.1 mg/ml in mammalian cell culture supernatants (Ghosh, 
2006).  Bioseparation also has to be very selective in nature due to the impurities and by-
product present in the solution, have chemical and physical properties similar to the 
target product.  The product also must meet the quality manufacturing criteria which is 
should be free from the endotoxin and pyrogens.  Most dilemma faces is the 
denaturation and degradation of the biological product towards the extremes of 
physicochemical condition such as pH and ionic strength, hydrodynamic conditions such 
as high shear rates, therefore bioseparation technique have to be „gentle‟ to avoid these 
conditions. 
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1.3 Scope of Research Work 
 The technique of downstream processing for mAbs production, which is used for 
initial recovery and isolation depends on the nature of the product, its own unique 
properties and characteristics, and the state of the product, as it leave the fermenter 
(Janson, 1993).  The aim of a protein, in this case is mAbs, purification process is three 
fold; to remove unwanted contaminants, to concentrate the desired product and to 
transfer the mAbs to an environment where it stable.  The analysis of the nature or 
fundamental properties of mAbs are relevant in the separation process such as size and 
for antibody molecular which is mAbs, possess much complex shape rather than the size 
of particulates matters such as cells, cell debris and macromolecular aggregates which 
far more simples and can be remove by separation technique easily.  Other then the size 
of the mAbs, the molecular weight is often used to separates the mAbs with the 
impurities by the separation technique.  After the physical properties been researched, 
the biochemistry properties also give the advantages in purification steps such as 
isoelectric point (pI) of a protein which is at certain pH value; the protein has the same 
amount of positive and negative charge which called as neutral in an overall sense.  
Above its pI a protein will has a net negative charge and vice versa (Ghosh, 2006).  
 These properties will be used and altered so that the objective of the downstream 
processing for the mAbs production is achieved.  The objective will be achieve trough 
the simulation process in which the SuperPro Designer
®
 will be use.  The simulator will 
gives a result in term of mass and concentrations of the Immunoglobulin G (IgG) for 
each stream present in the framework of the downstream processing that are introduced 
to the main frame of SPD.  
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1.4 Objectives 
 The objectives of this study is to propose the most suitable framework of 
downstream processing for monoclonal antibodies production in order to achieve highest 
purities of mAbs with the highest recovery of the Immunoglobulin G at the end of the 
process.  This study also aims to stimulate the propose framework using SuperPro 
Designer
®
 simulator in order to determine whether the propose framework will achieve 
the purities and recovery required. 
 
 
 
 
 
CHAPTER 2 
LITERATURE REVIEW 
2.1 Biotechnology 
 Biotechnology has undergone phenomenal growth in recent years.  Cellular and 
molecular biology, biochemistry and biophysics are fundamental areas that are linked 
together in this new world of industry.  Bioprocessing which deal with the manufacture 
of biochemical, biopharmaceuticals, foods, nutraceuticals and agrochemicals; is one of 
the major segments within biotechnology.  A plethora of new biologically derived 
products have been developed, approved and licensed which include in this study, 
monoclonal antibodies used for the treatment of cancer and multiple sclerosis (Ghosh, 
2006). 
 
2.2 Monoclonal Antibodies 
 Monoclonal antibodies (mAb or moAb) are monospecific antibodies that are 
alike because they are produced by one type of immune cell that are all clones of a 
single parent cell.  Given almost any substance, it is potential to create monoclonal 
antibodies that specifically bind to that substance; they can then serve to detect or purify 
that substance.  This has become an important tool in biochemistry, molecular biology 
and medicine.  When used as medications, the generic name ends in -mAbs 
("Nomenclature of monoclonal antibodies"). 
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Monoclonal antibodies are typically made by fusing the spleen cells from a 
mouse that has been immunized with the desired antigen with myeloma cells.  However, 
recent advances have allowed the use of rabbit B-cells.  Polyethylene glycol is used to 
fuse adjacent plasma membranes, but the success rate is low so a selective medium is 
used in which only fused cells can grow.  This is because myeloma cells have lost the 
ability to synthesize hypoxanthine-guanine-phosphoribosyl transferase (HGPRT), an 
enzyme necessary for the salvage synthesis of nucleic acids.  The figure shows the 
structure of a monoclonal antibody consist four regions which are VH that is variable 
region with heavy chain, CH for constant domain with heavy chain, VL stands for 
variable region with light chain and CL that is constant domain with light chain (A.A 
Shukla et al., 2007). 
 
 
Figure 2.1 Structure of a monoclonal antibody. 
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Table 2.1 : Several of approval monoclonal antibodies by USFDA 
Type Application Mechanism Mode 
infliximab rheumatoid arthritis, 
Crohn's disease 
inhibits TNF-α chimeric 
basiliximab Acute rejection of 
kidney transplants 
inhibits IL-2 on 
activated T cells  
chimeric 
abciximab  Prevent coagulation in 
coronary angioplasty 
inhibits the receptor 
GpIIb/IIIa on 
platelets 
chimeric 
daclizumab Acute rejection of 
kidney transplants 
inhibits IL-2 on 
activated T cells  
humanized 
gemtuzumab  relapsed acute myeloid 
leukaemia 
targets an antigen on 
leukemia cells  
humanized 
alemtuzumab  B cell leukemia targets an antigen 
CD52 on T- and B-
lymphocytes 
humanized 
rituximab Non-Hodgkin's 
Lymphoma 
targets 
phosphoprotein 
CD20 on B 
lymphocytes 
chimeric 
chimeric 
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2.3 Bioseparation Engineering 
The systematic study of the scientific and engineering principles utilized for the 
large scale purification of biological product is referred to bioseparation engineering.  It 
is a broader term from the downstream processing which specifically referred to the 
separation and purification segment of a bioprocess which followed some form of 
biological reaction (Ghosh, 2006).  Biological product can be categorized in different 
ways, such as based on chemical nature or application.  The figure below, illustrating the 
basis of bioseparation and the unit operation involved based on the differences of 
physical properties of the materials. 
 
 
Figure 2.2 Basis of bioseparation and the unit operation involved. 
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2.3.1 RIPP Scheme 
 A bioseparation process must combine high selectivity (or resolution) with high 
throughput (productivity).  To achieve these goals, a strategy has been developed, 
involving use of low resolution techniques first for recovery and isolation followed by 
high resolution techniques for purification and polishing (Gosh, 1999).  The RIPP 
scheme is which stand for Recovery, Isolation, Purification and Polishing steps is use as 
a method in the bioseparation technique. 
 
Table 2.2 : RIPP Scheme and typical unit operations categorized. 
 
 
 
 
